Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 15/20 | 0.78 |
| ▸ | PTK2 | Q05397 | 13/20 | 0.74 |
| ▸ | ULK1 | O75385 | 3/20 | 0.65 |
| ▸ | AURKA | O14965 | 2/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 4/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.60 |
| ▸ | STK16 | O75716 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | PAK4 | O96013 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493564 | 0.94 | PTK2B (0.75) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL3154998 | 0.91 | PTK2B (0.78) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL3154737 | 0.91 | PTK2B (0.78) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL5502355 | 0.90 | PTK2B (0.74) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL5493556 | 0.90 | PTK2B (0.74) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL3161179 | 0.90 | PTK2B (0.77) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL3146707 | 0.89 | PTK2B (0.75) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL3147828 | 0.88 | PTK2B (0.74) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL3155540 | 0.88 | PTK2B (0.74) | PTK2BPTK2ULK1AURKABRD4 | |
| SCHEMBL5495107 | 0.87 | PTK2B (0.84) | PTK2BPTK2ULK1AURKABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751143-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-02-14 | — | — | EP | claimed |
| US-7109337-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2006-09-19 | — | — | US | claimed |
| US-20060205945-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2006-09-14 | — | — | US | claimed |
| WO-2005111023-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050256145-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1751143-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7109337-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060205945-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2006-09-14 | — | — | US | disclosed |
| WO-2005111023-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256145-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205945-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2B 2693/4885PTK2 3522/4885ULK1 3324/4885 |
| US-20050256145-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2B 2693/4885PTK2 3522/4885ULK1 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.